News Center

Roblox lifts bookings forecast as spending defies tariff uncertainty

Roblox lifts bookings forecast as spending defies tariff uncertainty

By Zaheer Kachwala (Reuters) -Roblox raised its annual bookings forecast on Thursday and beat quarterly results estimates, a sign that spending on its vast library of user-generated videogames was holding up despite economic uncertainty driven by U.S. tariffs. Shares of the company rose more than 4%. The platform has aggressively tried to lure deep-pocketed older players with new game genres incl ...

2025-05-02 04:51:15
NYSE-parent ICE beats first-quarter profit estimates on robust trading volume

NYSE-parent ICE beats first-quarter profit estimates on robust trading volume

By Prakhar Srivastava (Reuters) -Intercontinental Exchange beat Wall Street estimates for first-quarter profit on Thursday, benefiting from strong trading volumes in energy and options segments.   Shares of the New York Stock Exchange parent were up 1.2%.  Global commodity and energy markets have experienced significant volatility due to shifting U.S. trade policies and concerns ove ...

2025-05-02 04:50:16
Hershey posts robust quarterly results on North America snacks demand

Hershey posts robust quarterly results on North America snacks demand

(Reuters) -Hershey posted a smaller-than-expected drop in sales for the first quarter and beat profit estimates on Thursday, helped by steady demand for its salty snacks business in North America. Sales in Hershey’s North America snack business, home to Dot’s pretzels and SkinnyPop popcorn, got a boost as the company reduced prices after several quarters of hikes. Its quarterly organic volume ...

2025-05-02 04:49:11
Arvinas stock tumbles following workforce reduction and trial removals

Arvinas stock tumbles following workforce reduction and trial removals

Investing.com -- Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its development plan. Despite reporting positive topline results from the Phase 3 VERITAC-2 trial and presenting promising data for its neuroscience program, the clinical-stage biotechnology fir ...

2025-05-02 04:48:05